Republic of China Vice President Chen Chien-jen, an epidemiologist with a background in researching hepatitis B, was the keynote speaker at the Taiwan Liver Health Forum sponsored by AmCham Taipei together with the American Institute in Taiwan (AIT) and the Ministry of Health and Welfare (MOHW). The event, held at the Howard-Plaza Hotel on October 3, was attended by 90-some guests from government, the medical community, and industry.
The idea for the forum grew out of a suggestion by AmCham Taipei’s Public Health Committee in the 2018 Taiwan White Paper that Taiwan strive to become the “Liver Health Center of Excellence in Asia.” Participants in the forum confirmed the validity of that goal, citing Taiwan’s pioneering work in past decades in controlling hepatitis B through vaccination and the government’s progress toward eradicating hepatitis C in the coming decade in line with World Health Organization objectives.
Hepatitis is endemic in this part of the world, and is considered a major health risk because it often leads to liver cancer. Among the points made by speakers at the forum were the importance of increasing the amount of screening conducted in Taiwan for hepatitis C. Although the effort would lead to higher healthcare expenditures in the near term, in the long-run it will substantially save costs due to reduced hospitalization and mortality, as well as heightened productivity.
Speakers also called for further expansion of clinical trials in Taiwan, more public education to raise awareness regarding liver health, and workplace programs to encourage more screening.
Opening remarks at the forum were delivered by AIT Director W. Brent Christensen and MOHW Deputy Minister Ho Chi-kung. In his half-hour keynote address, Vice President used a PowerPoint presentation to brief the audience on Taiwan’s past successes in combating liver disease. Other speakers were Dr. Kao Jia-horng, president of the Taiwan Association for the Study of the Liver; Dr. Pwu Raoh-fang, director of the MOHW National Hepatitis C Program Office; Dr. Homie Razavi, managing director of the U.S. Center for Disease Analysis; and Dr. Chiu Chang-fang, vice president of China Medical University Hospital.
Two panel discussions were moderated by Ramanathan Velayutham, Taiwan general manager for AbbVie Biopharmaceutical, and Pang Lai-li, Taiwan managing director for Merck Sharp & Dohme (MSD), respectively. Aside from the speakers, the panelists included Dr. Lee Po-chang, director-general of the National Health Insurance Administration, and Bristol-Myers Squibb General Manager Sophia Lee. AmCham Taipei President William Foreman gave closing remarks.
Platinum sponsors for the event were Abbvie, Bristol-Myers Squibb, and Gilead Sciences. MSD was a silver sponsor.